Daridorexant hydrochloride

Nxera sees pivotal study success for insomnia drugA Phase III study of daridorexant conducted by Nxera Pharma in South Korea met both primary and secondary endpoints in adult and elderly patients with insomnia, setting up a marketing application for the dual orexin receptor antagonist in the country in the first quarter.The trial achieved its main goal with daridorexant significantly improving subjective total sleep time (sTST) from baseline versus placebo at day 28. In addition, the drug also significantly improved the secondary efficacy endpoints of subjective latency to sleep onset and subjective wake after sleep onset.Daridorexant is already approved in Japan and marketed via an agreement between Nxera and Shionogi under the brand Quviviq. The therapy was discovered by Idorsia Pharmaceuticals, which markets it in the US, Canada and multiple European countries, while Simcere commercialises the drug in China and Hong Kong.Merck & Co. inks precision oncology pactMerck & Co. has struck a multi-year collaboration with Guardant Health aimed at bolstering its oncology pipeline. The tie-up, whose financial details were not disclosed, will make Guardant's Infinity Smart platform a tool for enrolling patients in Merck's cancer studies, while also supporting the creation of companion diagnostics tied to the pharma's future therapies.The companies will also partner on global commercialisation of drugs and companion diagnostics including in US, Asia-Pacific, UK and EU markets."As biomarkers become more central to therapy selection, our goal is to ensure that every trial has the molecular clarity needed to reach the right patients," said Helmy Eltoukhy, co-CEO at Guardant.

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO) Nxera plans to submit a marketing authorization application for daridorexant in South Korea in the first quarter of 2026, with approval expected in the first quarter of 2027 Tokyo, Japan and Cambridge, UK, 19 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that positive top-line results were obtained from a Phase 3 study conducted in South Korea evaluating daridorexant 50 mg in adult and elderly patients with insomnia. The Company plans to submit a marketing authorization application for daridorexant in South Korea in the first quarter of 2026, with approval in South Korea expected in the first quarter of 2027. Daridorexant is approved and being marketed in Japan as QUVIVIQ® under a commercialization agreement between Nxera and Shionogi. QUVIVIQ®, discovered by Idorsia Pharmaceuticals, is marketed by Idorsia in the US, Canada, and multiple European countries, and marketed by Simcere in China and Hong Kong. Insomnia, characterized by difficulties in sleep onset and/or sleep maintenance, impacts both physical and mental health. The condition is highly prevalent in South Korea, affecting 15-25% of the adult population, or approximately 6.5-11 million people. Mr. MinBok Lee, President and Representative Director of Nxera Pharma Korea, commented: “I Insomnia is highly prevalent in South Korea and represents a serious health condition that significantly affects patients’ daily lives. We are very encouraged by the positive results from this Phase 3 study, which represents a critical milestone as we prepare to submit a marketing authorization application in the first quarter of 2026. This progress brings patients in South Korea suffering from insomnia one step closer to gaining access to an important new treatment option. With QUVIVIQ® already available in the United States, Europe and Japan, we are committed to working towards making this medicine available to patients in South Korea as quickly as possible.” The successful Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of daridorexant in adult and elderly patients with insomnia. Patients were randomized to receive daridorexant 50 mg or placebo once daily for 28 days. The study met both its primary and secondary efficacy endpoints. At Day 28, daridorexant significantly improved the primary efficacy endpoint, the change from baseline in subjective total sleep time (sTST), compared with placebo (p<0.0001 for the 50 mg dose). Daridorexant also significantly improved the secondary efficacy endpoints, the change from baseline at Day 28 in subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO), compared with placebo (both p<0.0001 for the 50 mg dose). The incidence of adverse events was comparable between the daridorexant and placebo treatment groups. The rate of treatment-emergent adverse events (TEAEs) during the double-blind treatment period was comparable between placebo and daridorexant, reported in 13.41% of patients treated with daridorexant 50 mg and 14.81% for placebo. –END– Notes to Editors About Insomnia Disorder Insomnia disorder is defined as difficulty initiating or maintaining sleep, causing clinically significant distress or impairment in important areas of daytime functioning. As defined, this impact on sleep quantity or quality should be present for at least three nights per week, lasts for at least three months, and occurs despite an adequate opportunity to sleep. Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. The disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Research has shown that poor quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels. The goal of treatments for insomnia is to improve sleep quality and quantity, as well as daytime functioning, while avoiding adverse events and next-morning residual effects. Current recommended treatment of insomnia includes sleep hygiene therapy, cognitive behavioral therapy, and pharmacotherapy. According to multiple epidemiological studies, insomnia affects around 15% to 25% of the adult population in South Korea, or approximately 6.5-11 million people 1,2 . The condition is notably more prevalent among women and older adults. Recent data from Korea’s Health Insurance Review and Assessment Service (HIRA) revealed that the number of chronic insomnia patients treated has increased by 21% from 597,529 in 2018 to 722,440 in 2022. Of these patients, 50% are aged 60 or above, and 61% are women. 1 Epidemiology of Insomnia in Korean Adults: Prevalence and Associated Factors (Print ISSN 1738-6586 / On-line ISSN 2005-5013) 2 The Prevalence and Incidence of Insomnia in Korea during 2005 to 2013 / Print ISSN 1738-3684 / On-line ISSN 1976-3026) About the Orexin system Wake and sleep signaling is regulated by intricate neural circuitry in the brain. One key component of this process is the orexin system, which helps promote wakefulness. There are two forms of orexin neuropeptides – small protein-like molecules used by nerve cells (neurons) to communicate with each other in the brain – orexin A and orexin B. Orexin promotes wakefulness through its receptors OX1R and OX2R. Together, these neuropeptides and receptors make up the orexin system. The orexin system stimulates targeted neurons in the wake system – leading to the release of several chemicals (serotonin, histamine, acetylcholine, norepinephrine) – to promote wakefulness. Orexin regulates wake signaling, which might be overactive at night, preventing people with insomnia from falling asleep or staying asleep. Daridorexant is a dual orexin receptor antagonist (DORA) that equipotently antagonizes orexin receptors 1 and 2, consequently decreasing overactive wake signals throughout the entire night. About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, powered by its unique NxWave™ GPCR structure-based drug discovery platform, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma QUVIVIQ® is trademark of Idorsia Ltd. Enquiries Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations Maya Bennison, Communications Manager +81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.